Cellectar Biosciences (CLRB)
(Delayed Data from NSDQ)
$1.92 USD
-0.08 (-4.00%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $1.92 0.00 (0.00%) 7:52 PM ET
3-Hold of 5 3
F Value C Growth C Momentum F VGM
Cash flow Statements
Fiscal Year End for Cellectar Biosciences, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -37.98 | -28.60 | -24.12 | -15.09 | -14.09 |
Depreciation/Amortization & Depletion | 0.19 | 0.15 | 0.15 | 0.14 | 0.13 |
Net Change from Assets/Liabilities | 3.48 | 1.68 | 0.20 | 0.67 | 1.39 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 1.94 | 1.55 | 1.20 | 0.35 | 0.88 |
Net Cash From Operating Activities | -32.38 | -25.22 | -22.57 | -13.93 | -11.69 |
Property & Equipment | -0.86 | -0.23 | -0.14 | -0.06 | -0.02 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -0.86 | -0.23 | -0.14 | -0.06 | -0.02 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 22.94 | 9.61 | 1.25 | 60.36 | 9.02 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.18 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 22.94 | 9.61 | 1.25 | 60.55 | 9.02 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -10.30 | -15.84 | -21.46 | 46.55 | -2.70 |
Cash at Beginning of Period | 19.87 | 35.70 | 57.17 | 10.61 | 13.31 |
Cash at End of Period | 9.56 | 19.87 | 35.70 | 57.17 | 10.61 |
Diluted Net EPS | -3.11 | -4.05 | -4.30 | -7.60 | -18.40 |
Fiscal Year End for Cellectar Biosciences, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -21.58 | -37.98 | -30.53 | -16.80 |
Depreciation/Amortization & Depletion | NA | 0.09 | 0.19 | 0.12 | 0.08 |
Net Change from Assets/Liabilities | NA | -2.24 | 3.48 | 1.89 | 1.15 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 10.37 | 1.94 | 5.74 | 0.86 |
Net Cash From Operating Activities | NA | -13.36 | -32.38 | -22.78 | -14.71 |
Property & Equipment | NA | -0.02 | -0.86 | -0.60 | 0.00 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | -0.02 | -0.86 | -0.60 | 0.00 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 43.85 | 22.94 | 22.50 | 0.00 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | NA | 43.85 | 22.94 | 22.50 | 0.00 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | 30.47 | -10.30 | -0.88 | -14.71 |
Cash at Beginning of Period | NA | 9.56 | 19.87 | 19.87 | 19.87 |
Cash at End of Period | NA | 40.03 | 9.56 | 18.99 | 5.15 |
Diluted Net EPS | NA | -0.74 | -0.41 | -1.21 | -0.73 |